MX2019006013A - Composicion farmaceutica para evitar la adiccion a opioides. - Google Patents
Composicion farmaceutica para evitar la adiccion a opioides.Info
- Publication number
- MX2019006013A MX2019006013A MX2019006013A MX2019006013A MX2019006013A MX 2019006013 A MX2019006013 A MX 2019006013A MX 2019006013 A MX2019006013 A MX 2019006013A MX 2019006013 A MX2019006013 A MX 2019006013A MX 2019006013 A MX2019006013 A MX 2019006013A
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- pharmaceutical composition
- opioid addiction
- averting
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427365P | 2016-11-29 | 2016-11-29 | |
| PCT/US2017/063417 WO2018102294A1 (en) | 2016-11-29 | 2017-11-28 | A pharmaceutical composition for averting opioid addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006013A true MX2019006013A (es) | 2019-10-14 |
Family
ID=60766150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006013A MX2019006013A (es) | 2016-11-29 | 2017-11-28 | Composicion farmaceutica para evitar la adiccion a opioides. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10736961B2 (https=) |
| EP (1) | EP3548082B1 (https=) |
| JP (1) | JP7071975B2 (https=) |
| KR (1) | KR20190090820A (https=) |
| CN (1) | CN110072549A (https=) |
| AU (1) | AU2017366870B2 (https=) |
| BR (1) | BR112019010331A2 (https=) |
| CA (1) | CA3045116A1 (https=) |
| CL (1) | CL2019001385A1 (https=) |
| CO (1) | CO2019005247A2 (https=) |
| EA (1) | EA201991283A9 (https=) |
| IL (1) | IL266640B (https=) |
| MA (2) | MA45890B2 (https=) |
| MX (1) | MX2019006013A (https=) |
| MY (1) | MY200701A (https=) |
| PH (1) | PH12019501087A1 (https=) |
| WO (1) | WO2018102294A1 (https=) |
| ZA (1) | ZA201902967B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210043624A (ko) | 2018-08-10 | 2021-04-21 | 리제너론 파아마슈티컬스, 인크. | 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물 |
| EP4433500A1 (en) | 2021-11-19 | 2024-09-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
| US20240002491A1 (en) | 2022-04-27 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN101014364B (zh) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| BRPI0815370B8 (pt) | 2007-08-10 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
-
2017
- 2017-11-28 US US15/824,106 patent/US10736961B2/en active Active
- 2017-11-28 CA CA3045116A patent/CA3045116A1/en active Pending
- 2017-11-28 MX MX2019006013A patent/MX2019006013A/es unknown
- 2017-11-28 EP EP17817965.1A patent/EP3548082B1/en active Active
- 2017-11-28 EA EA201991283A patent/EA201991283A9/ru unknown
- 2017-11-28 IL IL266640A patent/IL266640B/en unknown
- 2017-11-28 AU AU2017366870A patent/AU2017366870B2/en active Active
- 2017-11-28 JP JP2019525911A patent/JP7071975B2/ja active Active
- 2017-11-28 CN CN201780073865.2A patent/CN110072549A/zh active Pending
- 2017-11-28 MY MYPI2019002915A patent/MY200701A/en unknown
- 2017-11-28 WO PCT/US2017/063417 patent/WO2018102294A1/en not_active Ceased
- 2017-11-28 MA MA45890A patent/MA45890B2/fr unknown
- 2017-11-28 KR KR1020197018394A patent/KR20190090820A/ko not_active Ceased
- 2017-11-28 MA MA046951A patent/MA46951A/fr unknown
- 2017-11-28 BR BR112019010331A patent/BR112019010331A2/pt unknown
-
2019
- 2019-05-13 ZA ZA2019/02967A patent/ZA201902967B/en unknown
- 2019-05-16 PH PH12019501087A patent/PH12019501087A1/en unknown
- 2019-05-22 CO CONC2019/0005247A patent/CO2019005247A2/es unknown
- 2019-05-22 CL CL2019001385A patent/CL2019001385A1/es unknown
-
2020
- 2020-07-02 US US16/920,178 patent/US11491222B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190090820A (ko) | 2019-08-02 |
| BR112019010331A2 (pt) | 2019-10-22 |
| EP3548082B1 (en) | 2024-05-15 |
| AU2017366870B2 (en) | 2024-09-19 |
| AU2017366870A1 (en) | 2019-06-06 |
| MA45890B2 (fr) | 2022-10-31 |
| US10736961B2 (en) | 2020-08-11 |
| EP3548082A1 (en) | 2019-10-09 |
| MY200701A (en) | 2024-01-11 |
| CA3045116A1 (en) | 2018-06-07 |
| CN110072549A (zh) | 2019-07-30 |
| US20180147280A1 (en) | 2018-05-31 |
| US20210060159A1 (en) | 2021-03-04 |
| MA46951A (fr) | 2019-10-09 |
| EA201991283A9 (ru) | 2019-11-27 |
| MA45890A1 (fr) | 2020-02-28 |
| JP7071975B2 (ja) | 2022-05-19 |
| CL2019001385A1 (es) | 2019-07-26 |
| JP2019535716A (ja) | 2019-12-12 |
| US11491222B2 (en) | 2022-11-08 |
| IL266640B (en) | 2022-09-01 |
| PH12019501087A1 (en) | 2019-08-19 |
| ZA201902967B (en) | 2024-10-30 |
| IL266640A (en) | 2019-07-31 |
| CO2019005247A2 (es) | 2019-05-31 |
| WO2018102294A1 (en) | 2018-06-07 |
| EA201991283A1 (ru) | 2019-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
| MX2024007358A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| CL2018000223A1 (es) | Combinación de antagonista de pd-1 con un inhibidor de egfr | |
| BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
| NI201700032A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico | |
| AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
| MX2023014921A (es) | Anticuerpo anti-cd154 con caracteristicas de union, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana. | |
| CO2019009586A2 (es) | Anticuerpos anti-gitr y métodos de uso de los mismos | |
| BR112018072681A2 (pt) | anticorpos anti-il-1r3 humanizados | |
| MX2019009122A (es) | ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI). | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| CO2019005247A2 (es) | Composición farmacéutica para evitar la adicción a opioides | |
| MX2025013942A (es) | Anticuerpos contra mucina 16 y metodos de uso de los mismos | |
| NZ735777A (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| HK1252514A1 (zh) | 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 | |
| EA202190504A1 (ru) | Способы лечения псориаза | |
| EA201500240A1 (ru) | Фармацевтическая композиция для коррекции симптомов или лечения астении и/или синдрома хронической усталости | |
| EA201990041A1 (ru) | Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении | |
| AU2020271352A8 (en) | Combinations of anti-ILDR2 antibodies and PD-1 antagonists | |
| AR112535A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa | |
| EA202092481A1 (ru) | Комбинированный способ лечения антагонистом cd73 и антагонистом оси pd-1/pd-l1 |